ABBOTT LABORATORIESABT
ABBOTT LABORATORIES Segments Disclosure
Segment and Geographic Area Information
________________________________________________________
Long-lived assets on a geographic basis primarily include property and equipment. It excludes goodwill, intangible assets, deferred tax assets, and financial instruments. At December 31, 2025, and 2024, long-lived assets totaled $22.2 billion and $18.5 billion, respectively, and in the U.S. such assets totaled $11.9 billion and $10.3 billion, respectively. Long-lived asset balances associated with other countries were not material on an individual country basis in either of the two years.
Abbott’s principal business is the discovery, development, manufacture, and sale of a broad line of healthcare products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, healthcare facilities, laboratories, physicians’ offices, and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. For segment reporting purposes, the Core Laboratory, Rapid Diagnostics, Molecular, and Point of Care businesses are aggregated and reported as the Diagnostic Products segment.
Medical Devices—Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. For segment reporting purposes, the Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation, and Diabetes Care businesses are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive Officer. The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
| Net Sales to External Customers (a) | Cost of Products Sold | Research and Development | Selling, General and Administrative | Operating Earnings (a) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Established Pharmaceuticals | $ | 5,536 | $ | 5,194 | $ | 5,066 | $ | (2,615) | $ | (2,444) | $ | (2,357) | $ | (176) | $ | (176) | $ | (173) | $ | (1,455) | $ | (1,341) | $ | (1,330) | $ | 1,290 | $ | 1,233 | $ | 1,206 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Nutritionals | 8,451 | 8,413 | 8,154 | (4,569) | (4,532) | (4,495) | (213) | (209) | (204) | (2,111) | (2,167) | (2,122) | 1,558 | 1,505 | 1,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Diagnostics | 8,937 | 9,341 | 9,988 | (4,984) | (4,995) | (5,264) | (602) | (656) | (698) | (1,611) | (1,617) | (1,593) | 1,740 | 2,073 | 2,433 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical Devices | 21,387 | 18,986 | 16,887 | (6,973) | (6,408) | (5,803) | (1,753) | (1,546) | (1,362) | (5,449) | (4,879) | (4,416) | 7,212 | 6,153 | 5,306 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | $ | 44,311 | $ | 41,934 | $ | 40,095 | $ | (19,141) | $ | (18,379) | $ | (17,919) | $ | (2,744) | $ | (2,587) | $ | (2,437) | $ | (10,626) | $ | (10,004) | $ | (9,461) | $ | 11,800 | $ | 10,964 | $ | 10,278 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | 17 | 16 | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales | $ | 44,328 | $ | 41,950 | $ | 40,109 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Corporate functions and plan benefit costs | (157) | (422) | (308) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net interest expense | (185) | (215) | (252) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | (664) | (673) | (644) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of Intangible assets | (1,682) | (1,878) | (1,966) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other, net (b) | (646) | (763) | (444) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings before Taxes | $ | 8,466 | $ | 7,013 | $ | 6,664 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (a) | In 2025, foreign exchange favorably impacted net sales and unfavorably impacted operating earnings. In 2024 and 2023, foreign exchange unfavorably impacted net sales and operating earnings. | ||||
| (b) | Other, net includes costs directly related to integrating acquired businesses and restructuring charges in 2025, 2024, and 2023. Charges and expenses for restructuring actions and other cost reduction initiatives were $287 million in 2025, $185 million in 2024, and $122 million in 2023. Other, net also includes: in 2025, $165 million for legal reserves related to a negotiated settlement; in 2024, a $143 million loss on the divestiture of a non-core business, as well as intangible and IPR&D asset impairments; and in 2023, charges of $100 million related to intangible asset impairments, partially offset by income arising from fair value changes in contingent consideration related to previous business acquisitions. | ||||
| Depreciation | Additions to Property and Equipment (c) | Total Assets | ||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | 2025 | 2024 | ||||||||||||||||||||||||||||||||||||||||||
| Established Pharmaceuticals | $ | 101 | $ | 96 | $ | 104 | $ | 169 | $ | 183 | $ | 185 | $ | 3,540 | $ | 3,087 | ||||||||||||||||||||||||||||||||||
| Nutritionals | 175 | 159 | 155 | 302 | 382 | 457 | 4,791 | 4,404 | ||||||||||||||||||||||||||||||||||||||||||
| Diagnostics | 533 | 521 | 499 | 761 | 758 | 750 | 8,273 | 7,678 | ||||||||||||||||||||||||||||||||||||||||||
| Medical Devices | 378 | 343 | 315 | 658 | 630 | 604 | 10,689 | 9,472 | ||||||||||||||||||||||||||||||||||||||||||
| Total Reportable Segments | 1,187 | 1,119 | 1,073 | 1,890 | 1,953 | 1,996 | $ | 27,293 | $ | 24,641 | ||||||||||||||||||||||||||||||||||||||||
| Other | 247 | 221 | 204 | 259 | 292 | 213 | ||||||||||||||||||||||||||||||||||||||||||||
| Total | $ | 1,434 | $ | 1,340 | $ | 1,277 | $ | 2,149 | $ | 2,245 | $ | 2,209 | ||||||||||||||||||||||||||||||||||||||
| (in millions) | 2025 | 2024 | ||||||||||||
| Total Reportable Segment Assets | $ | 27,293 | $ | 24,641 | ||||||||||
| Cash and investments | 9,857 | 8,853 | ||||||||||||
| Goodwill and intangible assets | 29,561 | 29,755 | ||||||||||||
All other (d) | 20,002 | 18,165 | ||||||||||||
| Total Assets | $ | 86,713 | $ | 81,414 | ||||||||||
________________________________________________________
| (c) | Amounts exclude property and equipment acquired through business acquisitions. | ||||
| (d) | All other includes long-term assets associated with the defined benefit plans of $7.5 billion in 2025 and $5.7 billion in 2024, and deferred tax assets of $8.1 billion in 2025 and $8.6 billion in 2024. | ||||
Net Sales to External Customers (e) | ||||||||||||||||||||
| (in millions) | 2025 | 2024 | 2023 | |||||||||||||||||
| United States | $ | 17,126 | $ | 16,323 | $ | 15,452 | ||||||||||||||
| Germany | 2,759 | 2,539 | 2,345 | |||||||||||||||||
| China | 1,907 | 2,113 | 2,253 | |||||||||||||||||
Switzerland | 1,871 | 1,747 | 1,638 | |||||||||||||||||
India | 1,871 | 1,817 | 1,750 | |||||||||||||||||
| Japan | 1,475 | 1,441 | 1,513 | |||||||||||||||||
United Kingdom | 1,340 | 1,185 | 991 | |||||||||||||||||
| All Other Countries | 15,979 | 14,786 | 14,168 | |||||||||||||||||
| Consolidated | $ | 44,328 | $ | 41,950 | $ | 40,109 | ||||||||||||||
________________________________________________________
| (e) | Sales by country are based on the country that sold the product. | ||||
Free Sentinel
Track for freeWant the next ABBOTT LABORATORIES segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment ABBOTT LABORATORIES's next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 20, 2026 | Showing above |
| 2024 | Feb 21, 2025 | |
| 2023 | Feb 16, 2024 | |
| 2022 | Feb 17, 2023 | |
| 2021 | Feb 18, 2022 | |
| 2020 | Feb 19, 2021 | |
| 2019 | Feb 21, 2020 | |
| 2016 | Feb 17, 2017 | |
| 2015 | Feb 19, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.